Sumary of Pfizer signs deal to allow other companies to produce its Covid-19 pill:
- In a statement issued Tuesday, Pfizer said it would grant a license for the antiviral pill to the Geneva-based Medicines Patent Pool, which would let generic drug companies produce the pill for use in 95 countries, making up about 53% of the world’s population.
- The deal excludes some large countries that have suffered devastating coronavirus outbreaks.
- “It’s quite significant that we will be able to provide access to a drug that appears to be effective and has just been developed, to more than 4 billion people,” Esteban Burrone, head of policy at the Medicines Patent Pool, said.
- Earlier this month, Pfizer said its pill cut the risk of hospitalization and death by nearly 90% in people with mild to moderate coronavirus infections.
- Independent experts recommended halting the company’s study based on its promising results.
- In a similar deal with the Medicines Patent Pool announced in October, Merck agreed to let other drugmakers make its Covid-19 pill, molnupiravir, available in 105 poorer countries.